EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model

Kerim Bora Yilmaz iD, Ece Tavukcuoglu iD, Hamdullah Yanik iD, Pelin Seçken iD, Ertugrul Celik iD, Sumeyra Guler iD, Mehmet Mert Hidiroglu iD, Ibrahim Burak Bahcecioglu iD, Ismail Erturk, Mehmet Ali Gulcelik iD, Derya Karakoc, Gunes Esendagli

Medicina · 22.03.2026 · 62 (3) · 600

DOI: 10.3390/medicina62030600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 22.03.2026. Verfasst von Kerim Bora Yilmaz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Research, Institute of Health Sciences, Hacettepe University, 06800 Ankara, Turkey. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Paclitaxel, Antibodies, Monoclonal, Humanized, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: A combination of chemotherapy and immunotherapy may improve cancer treatment outcomes; however, determining which patient groups will benefit from immunotherapy is critical. Triple-negative breast cancer (TNBC) achieves limited benefit from immune checkpoint inhibitors (ICIs) and anti-PD-L1 blockade therapy. Materials and Methods: In this study, PD-L1 expression levels in myeloid-derived cells in the tumor microenvironment were determined in an experimental TNBC model.

Results

Compared with tumor cells, granulocytes, monocytes, and macrophages had significantly higher PD-L1 expression. CD206+ tumor-associated macrophages (TAMs) expressed the highest level of PD-L1. PD-L1 positivity in TAMs was also significantly high in the lung, liver, lymph node, and spleen. Despite treatment initiation in late-stage tumorigenesis, the combination of paclitaxel and the anti-PD-L1 monoclonal antibody atezolizumab significantly reduced tumor growth. In addition, lung metastasis burden was reduced with combined treatment compared with chemotherapy or anti-PD-L1 monotherapy alone.

Conclusions

As a result, alterations in PD-L1+ myeloid cells and immune infiltration can be associated with atezolizumab and paclitaxel therapy success in triple-negative breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPaclitaxelAntibodies, Monoclonal, HumanizedB7-H1 AntigenMyeloid CellsAnimalsFemaleHumansMiceImmune Checkpoint InhibitorsTumor MicroenvironmentDisease Models, Animal

Stichwörter der Autor:innen

atezolizumabcombination therapyimmune checkpoint inhibitorsmetastasispaclitaxeltreatment responsetriple-negative breast cancertumor immune microenvironment

Substanzen

atezolizumabPaclitaxelAntibodies, Monoclonal, HumanizedB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical and Surgical Research, Institute of Health Sciences, Hacettepe University, 06800 Ankara, Turkey.
  • Department of General Surgery, Gulhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Turkey.
  • Department of Basic Oncology, Cancer Institute, Hacettepe University, 06800 Ankara, Turkey.
  • Department of Pathology, Gulhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Turkey.
  • Department of Surgical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Turkey.
  • Department of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Turkey.

ORCID-Profile: Kerim Bora Yilmaz, Ece Tavukcuoglu, Hamdullah Yanik, Pelin Seçken, Ertugrul Celik, Sumeyra Guler, Mehmet Mert Hidiroglu, Ibrahim Burak Bahcecioglu, Mehmet Ali Gulcelik

Zitieren

APA

Yilmaz, K. B., Tavukcuoglu, E., Yanik, H., Seçken, P., Celik, E., Guler, S., Hidiroglu, M. M., Bahcecioglu, I. B., Erturk, I., Gulcelik, M. A., Karakoc, D., & Esendagli, G. (2026). Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina, 62(3), 600. https://doi.org/10.3390/medicina62030600

Vancouver

Yilmaz KB, Tavukcuoglu E, Yanik H, Seçken P, Celik E, Guler S, et al. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina. 2026;62(3):600. doi:10.3390/medicina62030600

BibTeX
@article{Yilmaz2026,
  author = {Yilmaz, Kerim Bora and Tavukcuoglu, Ece and Yanik, Hamdullah and Seçken, Pelin and Celik, Ertugrul and Guler, Sumeyra and Hidiroglu, Mehmet Mert and Bahcecioglu, Ibrahim Burak and Erturk, Ismail and Gulcelik, Mehmet Ali and Karakoc, Derya and Esendagli, Gunes},
  title = {Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {3},
  pages = {600},
  doi = {10.3390/medicina62030600}
}
Kostenlos starten →